Minoru Takata

Title: Minoru Takata: Innovator in Anticancer Research

Introduction

Minoru Takata is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of cancer research through his innovative work on anticancer agents. His research focuses on enhancing the sensitivity of cells to DNA-damaging factors, which is crucial for developing effective cancer therapies.

Latest Patents

Minoru Takata holds a patent for a target of an anticancer agent. This patent provides a mutant Rad51 paralog gene, wherein a protein encoded by the gene shows an activity for enhancing the sensitivity of a cell to a DNA-damaging factor. The patent also includes a mutant Rad51 paralog peptide, a transformed cell containing the gene, and methods for screening drugs that have DNA-damaging actions. This invention enables the screening of novel anticancer agents that can enhance the effectiveness of cancer therapies.

Career Highlights

Minoru Takata is associated with the Japan Science and Technology Corporation, where he continues to advance his research in cancer treatment. His work has been instrumental in paving the way for new therapeutic strategies that target cancer cells more effectively.

Collaborations

Minoru Takata collaborates with Shunichi Takeda, a fellow researcher in the field. Their partnership has contributed to the development of innovative solutions in cancer therapy.

Conclusion

Minoru Takata's contributions to anticancer research highlight the importance of innovation in developing effective treatments for cancer. His work continues to inspire advancements in the field, aiming for a future where cancer therapies are more efficient and targeted.